Ulysses Neuroscience Ltd. provides a comprehensive translational platform to evaluate classical and next-generation psychedelics.
From behavioural and EEG models to advanced biomarkers and human iPSC-derived neurons, our HPRA- and AAALAC-accredited facilities deliver robust, translatable data. With full authorization to hold and test Schedule I compounds, we enable our partners to advance psychedelic research programmes with speed, compliance, and scientific rigor.
Pharma & biotech companies developing psychedelic-based therapeutics
Companies focusing on non-hallucinogenic analogues and neuroplastogens
Researchers requiring translational biomarkers to align preclinical and clinical data
Integrated translational pipeline:
in vivo → in vitro → biomarkers → clinical
Regulatory compliance: HPRA (Ireland) & AAALAC (North America) approved
Schedule I license: unique competitive advantage in psychedelic research
Expert team: 20+ years’ experience in neuropharmacology and translational biomarkers
Global partnerships: trusted by pharma, biotech, and foundations worldwide
Our preclinical psychedelic portfolio combines validated rodent models with state-of-the-art behavioural, EEG, and biomarker endpoints. These models capture the core domains of depression, anxiety, and schizophrenia, and are pharmacologically validated with reference compounds such as ketamine and psilocybin.
They provide a robust and translatable platform to evaluate both classical psychedelics and next-generation non-hallucinogenic neuroplastogens, enabling mechanism-driven discovery and accelerating development toward clinical application.
At Ulysses Neuroscience Ltd., we apply a suite of validated biomarker technologies to investigate the mechanisms and translational signatures of psychedelics. By combining Odyssey CLx near-infrared imaging, MSD QuickPlex SQ 120 electrochemiluminescence, and Luminex 200 multiplex immunoassays, we quantify α-tubulin post-translational modifications, synaptic proteins, neurotrophic factors, and cytokines in plasma, CSF, brain tissue, and cell culture models. This integrated approach ensures direct comparability between preclinical and clinical studies, de-risking the development of classical and next-generation psychedelics.
With extensive expertise in human iPSCs neuroscience, we deliver fully validated, disease-relevant neuronal models to accelerate translational research from molecular mechanisms to clinical application.
Our PK/PD and biocollection platforms provide the essential bridge between preclinical discovery and clinical translation. Through longitudinal and terminal sampling in rodents and dogs, combined with a unique biocollection of human plasma and CSF from patients with depression and schizophrenia, we deliver a powerful translational framework. Importantly, Ulysses provides a customized Clinical Sampling Kit that is distributed across clinical sites to standardize collection procedures. Each kit is fully validated for biomarker analysis using our Odyssey CLx, MSD QuickPlex SQ 120, and Luminex 200 platforms, ensuring data quality and comparability across sites. All samples are stored under HPRA-approved biobanking procedures, ensuring regulatory compliance and long-term availability for exploratory and confirmatory studies.
Thermo Q Exactive with Ultimate 3000 UPLC – Bioanalysis
Clinical Biocollection Workflow
Cytoskeletal Biomarkers in Major Depressive Disorder (MDD)
PK/PD, Bioanalysis and Clinical Biocollection in Depression. Longitudinal and terminal sampling allow plasma, serum, and CSF collection for PK/PD and biomarker studies. Bioanalysis is performed on the Thermo Q Exactive coupled with Ultimate 3000 UPLC, enabling high-resolution LC-MS/MS quantification. Representative chromatograms illustrate internal standard detection (Diclofenac and Glipizide), used for matrix-matched quantification across CNS samples. Clinical biocollection further integrates preclinical and clinical pipelines. Representative biomarker analyses in Major Depressive Disorder (MDD) show increased acetylated α-tubulin in both orbitofrontal cortex tissue and plasma compared with healthy controls, confirming translational relevance of microtubule biomarkers. Data are mean ± SEM. Student’s t-test, *p < 0.05, **p < 0.01 vs. control. Group sizes: n = 12–34.
Connor J Maltby, Adam Klein, Enya Paschen, Jessica Pinto, Dino Dvorak, Joseph R Hedde, Ashley N Hanks, Massimiliano Bianchi, Zoë A Hughes
Partner with Ulysses Neuroscience Ltd.— your vanguard CRO and translational partner.
Let’s redefine what’s possible in neuroscience.
© 2026 Ulysses Neuroscience Ltd. All Rights Reserved
